ABTAbbott Laboratories
Abbott Laboratories (ABT) is a global healthcare company with a dominant presence in diagnostics, medical devices, and pharmaceuticals. The company’s next catalyst is Oct 15, 2026 — Key Fall 2026 Diabetes & Cardiology Conferences (Libre & Structural Heart Data), where it will present data on its Libre glucose monitoring system and structural heart devices. This event will test the strength of its innovation pipeline and its ability to maintain market share in competitive segments.
- Revenue of $44.03B in 2026 reflects a 5.7% YoY growth, driven by strong performance in diagnostics and medical devices.
- Net income of $5.83B and free cash flow of $9.10B highlight the company’s profitability and cash generation.
- Debt-to-equity of 0.25x suggests a conservative capital structure, with 13.2% net margin underscoring operational efficiency.
The schedule
- Thu15Oct
Major fall medical meetings where Abbott is expected to present updated FreeStyle Libre clinical and real‑world data, along with structural heart and electrophysiology results that can influence long-term share gains versus MDT, BSX and other device peers.
- Wed21Oct
Q3 2026 results and any revision to full-year 2026 guidance, with focus on sustainability of Medical Devices growth (Libre, structural heart), integration of the Exact Sciences assets, and any improvement in Nutrition following recent weakness.
- Tue15Dec
Year-end clarity on 2027 US reimbursement schedules and commercial pricing trends for key Abbott device and diagnostic lines under President Trump’s administration, including potential changes in Medicare and private-payer reimbursement for continuous glucose monitoring and cardiovascular devices.
- Tue9Feb
Full-year 2026 wrap-up with Q4 results and initial 2027 guidance, highlighting durability of Libre and structural heart growth, synergy capture from the Exact Sciences acquisition, and visibility on margin normalization after GAAP earnings volatility.
- Wed28Apr
Q1 2027 results as the first checkpoint against 2027 guidance, with focus on early-year procedure volumes, Libre adoption trends, and any incremental signal on reimbursement or pricing under evolving US health policy.
- Wed28Jul
Past
- Thu16Jul
Actual outcome: Bull · $103.06 at outcome
Abbott Laboratories delivered a strong Q2 earnings report, posting adjusted EPS of $1.31 that beat estimates and raising its full-year 2026 earnings outlook. The stock rallied past the bull target as robust growth in the Medical Devices and Cancer Diagnostics segments, along with positive traction from the Exact Sciences acquisition, successfully offset ongoing weakness in the Nutrition division.
Abbott Laboratories delivered a strong Q2 earnings report, posting adjusted EPS of $1.31 that beat estimates and raising its full-year 2026 earnings outlook. The stock rallied past the bull target as robust growth in the Medical Devices and Cancer Diagnostics segments, along with positive traction from the Exact Sciences acquisition, successfully offset ongoing weakness in the Nutrition division.
- Fri20Feb
Actual outcome: Bear · $106.05 at outcome
Abbott met Q4 EPS expectations but reported a sizable revenue miss, falling 3% short of analyst projections, primarily due to weakness in the Nutrition segment and the continued decline in COVID-19 diagnostics. Despite management guiding for solid 2026 EPS growth, the revenue shortfall and segment headwinds triggered a steep post-earnings sell-off, driving the stock significantly below the bear floor of $118.00.
Abbott met Q4 EPS expectations but reported a sizable revenue miss, falling 3% short of analyst projections, primarily due to weakness in the Nutrition segment and the continued decline in COVID-19 diagnostics. Despite management guiding for solid 2026 EPS growth, the revenue shortfall and segment headwinds triggered a steep post-earnings sell-off, driving the stock significantly below the bear floor of $118.00.
- Tue27Jan
Actual outcome: Bull · $112.26 at outcome
The market prioritized the long-term growth narrative, driving the stock toward the bull target despite significant near-term headwinds. Although Q4 revenue was initially disappointing and a major recall of glucose sensors was announced during the digestion period, the stock rallied to $112.34. This move was fueled by management's guidance for 10% EPS growth in 2026 and the confirmed robust double-digit growth in the FreeStyle Libre segment, signaling that investors viewed the negative news as a manageable, temporary setback.
The market prioritized the long-term growth narrative, driving the stock toward the bull target despite significant near-term headwinds. Although Q4 revenue was initially disappointing and a major recall of glucose sensors was announced during the digestion period, the stock rallied to $112.34. This move was fueled by management's guidance for 10% EPS growth in 2026 and the confirmed robust double-digit growth in the FreeStyle Libre segment, signaling that investors viewed the negative news as a manageable, temporary setback.